The Japanese Breast Cancer Society clinical practice guideline for epidemiology and prevention of breast cancer
详细信息 查看全文
- 作者：Naruto Taira (1)
Masami Arai (2)
Masahiko Ikeda (3)
Motoki Iwasaki (4)
Hitoshi Okamura (5)
Kiyoshi Takamatsu (6)
Seiichiro Yamamoto (7)
Shozo Ohsumi (8)
Hirofumi Mukai (9)
1. Department of Breast and Endocrine Surgery ; Okayama University Hospital ; 2-5-1 Shikata-cho ; Okayama ; 700-8558 ; Japan
2. Clinical Laboratory of Genetic Diagnosis ; The Cancer Institute Hospital of Japanese Foundation for Cancer Research ; Tokyo ; Japan
3. Department of Breast and Thyroid Surgery ; Fukuyama City Hospital ; Fukuyama ; Hiroshima ; Japan
4. Epidemiology and Prevention Division ; Research Center for Cancer Prevention and Screening ; National Cancer Center Research Institute ; Tokyo ; Japan
5. Department of Psychosocial Rehabilitation ; Institute of Biomedical and Health Sciences ; Hiroshima University ; Hiroshima ; Japan
6. Department of Obstetrics and Gynecology ; Tokyo Dental College Ichikawa General Hospital ; Ichikawa ; Chiba ; Japan
7. Public Health Policy Research Division ; Research Center for Cancer Prevention and Screening ; National Cancer Center Research Institute ; Tokyo ; Japan
8. Department of Breast Oncology ; National Hospital Organization Shikoku Cancer Center ; Matsuyama ; Ehime ; Japan
9. Division of Breast and Medical Oncology ; National Cancer Center Hospital East ; Kashiwa ; Chiba ; Japan - 刊名：Breast Cancer
- 出版年：2015
- 出版时间：January 2015
- 年：2015
- 卷：22
- 期：1
- 页码：16-27
- 全文大小：223 KB
- 参考文献：1. Kawamura T, Sobue T. Comparison of breast cancer mortality in five countries:France, Italy, Japan, the UK and the USA from the WHO mortality database (1960鈥?000). Jpn J Clin Oncol. 2005;35:758鈥?. CrossRef
2. Katanoda K, Qiu D. Comparison of time trends in female breast cancer incidence (1973 1997) in East Asia, Europe and USA, from cancer incidence in five Continents, Vols IV VIII. Jpn J Clin Oncol. 2007;37:638鈥?. CrossRef
3. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington DC: AICR; 2007.
4. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569鈥?8. CrossRef
5. Suzuki R, Iwasaki M, Inoue M, Sasazuki S, Sawada N, Yamaji T, et al. Japan Public Health Center-based Prospective Study Group. Body weight at age 20聽years, subsequent weight change and breast cancer risk defined by estrogen and progesterone receptor status-the Japan public health center-based prospective study. Int J Cancer. 2011;129:1214鈥?4. CrossRef
6. Green J, Cairns BJ, Casabonne D, Wright FL, Reeves G, Beral V. Million Women Study collaborators. Height and cancer incidence in the Million Women Study:prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. Lancet Oncol. 2011;12:785鈥?4. CrossRef
7. White KK, Park SY, Kolonel LN, Henderson BE, Wilkens LR. Body size and breast cancer risk: the multiethnic cohort. Int J Cancer. 2012;131:E705鈥?6. CrossRef
8. Sung J, Song YM, Lawlor DA, Smith GD, Ebrahim S. Height and site-specific cancer risk: a cohort study of a Korean adult population. Am J Epidemiol. 2009;170:53鈥?4. CrossRef
9. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev. 1993;15:36鈥?7.
10. Kawai M, Minami Y, Kuriyama S, Kakizaki M, Kakugawa Y, Nishino Y, et al. Reproductive factors, exogenous female hormone use and breast cancer risk in Japanese: the Miyagi cohort study. Cancer Causes Control. 2010;21:135鈥?5. CrossRef
11. Tamakoshi K, Yatsuya H, Wakai K, Suzuki S, Nishio K, Lin Y, et al. JACC Study Group. Impact of menstrual and reproductive factors on breast cancer risk in Japan: results of the JACC study. Cancer Sci. 2005;96:57鈥?2. CrossRef
12. Iwasaki M, Otani T, Inoue M, Sasazuki S, Tsugane S. Japan Public Health Center-based prospective study group. Role and impact of menstrual and reproductive factors on breast cancer risk in Japan. Eur J Cancer Prev. 2007;16:116鈥?3. CrossRef
13. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breast feeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002;360:187鈥?5. CrossRef
14. Tokunaga M, Land CE, Yamamoto T, Asano M, Tokuoka S, Ezaki H, et al. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1980. Radiat Res. 1987;112:243鈥?2. CrossRef
15. Tokunaga M, Land CE, Tokuoka S, Nishimori I, Soda M, Akiba S. Incidence of female breast cancer among atomic bomb survivors, 1950鈥?985. Radiat Res. 1994;138:209鈥?3. CrossRef
16. Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, Boice JD Jr. Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res. 2002;158:220鈥?5. CrossRef
17. Doody MM, Lonstein JE, Stovall M, Hacker DG, Luckyanov N, Land CE. Breast cancer mortality after diagnostic radiography: findings from the US scoliosis cohort study. Spine. 2000;25:2052鈥?3 (Phila Pa 1976). CrossRef
18. Henderson TO, Amsterdam A, Bhatia S, Hudson MM, Meadows AT, Neglia JP, et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med. 2010;152:444鈥?5. CrossRef
19. Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WD Jr, Simpson JF. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet. 2003;361:125鈥?. CrossRef
20. Page DL, Dupont WD, Jensen RA. Papillary apocrine change of the breast: associations with atypical hyperplasia and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 1996;5:29鈥?2.
21. Dupont WD, Page DL, Parl FF, Vnencak-Jones CL, Plummer WD Jr, Rados MS, et al. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med. 1994;331:10鈥?. CrossRef
22. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312:146鈥?1. CrossRef
23. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005;353:229鈥?7. CrossRef
24. Kabat GC, Jones JG, Olson N, Negassa A, Duggan C, Ginsberg M, et al. A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer. Cancer Causes Control. 2010;21:821鈥?. CrossRef
25. Ma L, Boyd NF. Atypical hyperplasia and breast cancer risk: a critique. Cancer Causes Control. 1992;3:517鈥?5. CrossRef
26. Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer. 1997;71:800鈥?. CrossRef
27. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, et al. WHI investigators. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304(15):1684鈥?2. CrossRef
28. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047鈥?9. CrossRef
29. Collins JA, Blake JM, Crosignani PG. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update. 2005;11:545鈥?0. CrossRef
30. Greiser CM, Greiser EM, D枚ren M. Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials. Hum Reprod Update. 2005;11:561鈥?3. CrossRef
31. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3聽N cohort study. Breast Cancer Res Treat. 2008;107:103鈥?1. CrossRef
32. Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women鈥檚 Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012;13:476鈥?6. CrossRef
33. Saeki T, Sano M, Komoike Y, Sonoo H, Honjyo H, Ochiai K, et al. No increase of breast cancer incidence in Japanese women who received hormone replacement therapy: overview of a case-control study of breast cancer risk in Japan. Int J Clin Oncol. 2008;13:8鈥?1. CrossRef
34. Kawai M, Minami Y, Kuriyama S, Kakizaki M, Kakugawa Y, Nishino Y, et al. Reproductive factors, exogenous female hormone use and breast cancer risk in Japanese: the Miyagi cohort study. Cancer Causes Control. 2010;21:135鈥?5. CrossRef
35. Nagata C, Mizoue T, Tanaka K, Tsuji I, Wakai K, Inoue M, et al. Research group for the development and evaluation of cancer prevention strategies in Japan. Alcohol drinking and breast cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. 2007;37:568鈥?4. CrossRef
36. Suzuki R, Iwasaki M, Inoue M, Sasazuki S, Sawada N, Yamaji T, et al. Japan Public Health Center-Based Prospective Study Group. Alcohol consumption-associated breast cancer incidence and potential effect modifiers: the Japan public health center-based prospective study. Int J Cancer. 2010;127:685鈥?5. CrossRef
37. Kawai M, Minami Y, Kakizaki M, Kakugawa Y, Nishino Y, Fukao A, et al. Alcohol consumption and breast cancer risk in Japanese women: the Miyagi cohort study. Breast Cancer Res Treat. 2011;128:817鈥?5. CrossRef
38. Nagata C, Mizoue T, Tanaka K, Tsuji I, Wakai K, Inoue M, et al. Research group for the development and evaluation of cancer prevention strategies in Japan. Tobacco smoking and breast cancer risk: an evaluation based on a systematic review of epidemiological evidence among the Japanese population. Jpn J Clin Oncol. 2006;36:387鈥?4. CrossRef
39. Xue F, Michels KB. Intrauterine factors and risk of breast cancer: a systematic review and meta-analysis of current evidence. Lancet Oncol. 2007;8:1088鈥?00. CrossRef
40. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13:1141鈥?1. CrossRef
41. Nagata C, Hu YH, Shimizu H. Effects of menstrual and reproductive factors on the risk of breast cancer: meta-analysis of the case-control studies in Japan. Jpn J Cancer Res. 1995;86:910鈥?. CrossRef
42. Suzuki S, Kojima M, Tokudome S, Mori M, Sakauchi F, Fujino Y, Japan Collaborative Cohort Study Group, et al. Effect of physical activity on breast cancer risk: findings of the Japan collaborative cohort study. Cancer Epidemiol Biomarkers Prev. 2008;17:3396鈥?01. CrossRef
43. Suzuki R, Iwasaki M, Yamamoto S, Inoue M, Sasazuki S, Sawada N, Japan Public Health Center-based Prospective Study Group, et al. Leisure-time physical activity and breast cancer risk defined by estrogen and progesterone receptor status鈥搕he Japan public health center-based prospective study. Prev Med. 2011;52:227鈥?3.
44. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer:a meta-analysis. Int J Cancer. 2007;121:856鈥?2. CrossRef
45. Boyle P, Boniol M, Koechlin A, Robertson C, Valentini F, Coppens K, et al. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer. 2012;107:1608鈥?7. CrossRef
46. Dong JY, Zhang L, He K, Qin LQ. Dairy consumption and risk of breast cancer:a meta-analysis of prospective cohort studies. Breast Cancer Res Treat. 2011;127:23鈥?1. CrossRef
47. Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S. Japan public health center-based prospective study on cancer cardiovascular diseases group. Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst. 2003;95:906鈥?3. CrossRef
48. Iwasaki M, Inoue M, Otani T, Sasazuki S, Kurahashi N, Miura T, Japan Public Health Center-Based Prospective Study Group, et al. Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan public health center-based prospective study group. J Clin Oncol. 2008;26:1677鈥?3. CrossRef
49. Nishio K, Niwa Y, Toyoshima H, Tamakoshi K, Kondo T, Yatsuya H, et al. Consumption of soy foods and the risk of breast cancer: findings from the Japan Collaborative Cohort (JACC) Study. Cancer Causes Control. 2007;18:801鈥?. CrossRef
50. Trock BJ, Hilakivi-Clarke L, Clarke R. Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst. 2006;98:459鈥?1. CrossRef
51. Bosetti C, Scotti L, Negri E, Talamini R, Levi F, Franceschi S, et al. Benign ovarian cysts and breast cancer risk. Int J Cancer. 2006;119:1679鈥?2. CrossRef
52. Knight JA, John EM, Milne RL, Dite GS, Balbuena R, Shi EJ, et al. An inverse association between ovarian cysts and breast cancer in the breast cancer family registry. Int J Cancer. 2006;118:197鈥?02. CrossRef
53. Knight JA, Lesosky M, Blackmore KM, Voigt LF, Holt VL, Bernstein L, et al. Ovarian cysts and breast cancer: results from the women鈥檚 contraceptive and reproductive experiences study. Breast Cancer Res Treat. 2008;109:157鈥?4. CrossRef
54. Talamini R, Franceschi S, Favero A, Negri E, Parazzini F, La Vecchia C. Selected medical conditions and risk of breast cancer. Br J Cancer. 1997;75:1699鈥?03. CrossRef
55. Weiss HA, Brinton LA, Potischman NA, Brogan D, Coates RJ, Gammon MD, et al. Breast cancer risk in young women and history of selected medical conditions. Int J Epidemiol. 1999;28:816鈥?3. CrossRef
56. Miller MD, Marty MA, Broadwin R, Johnson KC, Salmon AG, Winder B, California Environmental Protection Agency, et al. The association between exposure to environmental tobacco smoke and breast cancer:a review by the california environmental protection agency. Prev Med. 2007;44:93鈥?06. CrossRef
57. Pirie K, Beral V, Peto R, Roddam A, Reeves G, Green J. Million Women Study Collaborators. Int J Epidemiol. 2008;37:1069鈥?9. CrossRef
58. Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O鈥橫eara ES, et al. Risk factors for breast cancer for women aged 40 to 49聽years: a systematic review and meta-analysis. Ann Intern Med. 2012;156:635鈥?8. CrossRef
59. Kahlenborn C, Modugno F, Potter DM, Severs WB. Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc. 2006;81:1290鈥?02. CrossRef
60. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives:collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347:1713鈥?7. CrossRef
61. Megdal SP, Kroenke CH, Laden F, Pukkala E, Schernhammer ES. Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer. 2005;41:2023鈥?2. CrossRef
62. Schwartzbaum J, Ahlbom A, Feychting M. Cohort study of cancer risk among male and female shift workers. Scand J Work Environ Health. 2007;33:336鈥?3. CrossRef
63. Pronk A, Ji BT, Shu XO, Xue S, Yang G, Li HL, et al. Night-shift work and breast cancer risk in a cohort of Chinese women. Am J Epidemiol. 2010;171:953鈥?. CrossRef
64. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879鈥?6. CrossRef
65. Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91:1541鈥?. CrossRef
66. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296鈥?00. CrossRef
67. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. Raloxifene use for the heart (RUTH) trial investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125鈥?7. CrossRef
68. Goss PE, Ingle JN, Al茅s-Mart铆nez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, NCIC CTG MAP.3 Study Investigators, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364:2381鈥?1. CrossRef
69. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117鈥?0. CrossRef
70. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Genetic/familial high-risk assessment: breast and ovarian. ver1. 2013.
71. Pijep A, Andrieu N, Easton DF, Kesminiene A, Cardis E, Nogu猫s C, GENEPSO, EMBRACE, HEBON, et al. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations:retrospective cohort study (GENE-RAD-RISK). BMJ. 2012;345:e5660. CrossRef
72. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, American Cancer Society Breast Cancer Advisory Group, et al. American cancer society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75鈥?9. CrossRef
73. Kuhl C, Weigel S, Schrading S, Arand B, Bieling H, K枚nig R, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol. 2010;28:1450鈥?. CrossRef
74. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van鈥檛 Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol. 2004;22:1055鈥?2. CrossRef
75. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:159鈥?4. CrossRef
76. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967鈥?5. CrossRef
77. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, National Surgical Adjuvant Breast and Bowel Project, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National surgical adjuvant breast and bowel project (NSABP-P1) breast cancer prevention trial. JAMA. 2001;286:2251鈥?. CrossRef
78. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101:80鈥?. CrossRef
79. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967鈥?5. CrossRef
80. Hermsen BB, Olivier RI, Verheijen RH, van Beurden M, de Hullu JA, Massuger LF, et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer. 2007;96:1335鈥?2.
81. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123:627鈥?5. CrossRef
82. Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol. 2010;28:3411鈥?. CrossRef
83. Pfeiler G, K枚nigsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol. 2011;29:2653鈥?. CrossRef
84. Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol. 2005;23:1370鈥?. CrossRef
85. Camoriano JK, Loprinzi CL, Ingle JN, Therneau TM, Krook JE, Veeder MH. Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol. 1990;8:1327鈥?4.
86. Ibrahim EM, Al-Homaidh A. Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies. Med Oncol. 2011;28:753鈥?5. CrossRef
87. Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104:815鈥?0. CrossRef
88. Holmes MD, Murin S, Chen WY, Kroenke CH, Spiegelman D, Colditz GA. Smoking and survival after breast cancer diagnosis. Int J Cancer. 2007;120:2672鈥?. CrossRef
89. Dong JY, Qin LQ. Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies. Breast Cancer Res Treat. 2011;125:315鈥?3. CrossRef
90. Nechuta SJ, Caan BJ, Chen WY, Lu W, Chen Z, Kwan ML, et al. Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. Am J Clin Nutr. 2012;96:123鈥?2. CrossRef - 刊物主题：Surgical Oncology; Oncology; Surgery; Cancer Research;
- 出版者：Springer Japan
- ISSN：1880-4233
文摘